Staphylococcal Skin Infections Clinical Trial
Official title:
A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-resistant Staphylococcus Aureus (MRSA)
This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin. The purpose of this study is to compare infection-related hospital length of stay, along with a number of participant-reported outcomes, between participants with complicated skin and soft tissue infection treated with daptomycin and vancomycin.
Eligible participants will be recruited within 24 hours of hospital admission for cSSSI due to suspected or documented Methicillin-resistant Staphylococcus Aureus (MRSA), and who are anticipated to require IV antibiotics effective against MRSA and at least 3 days of hospitalization for management of cSSSI. The primary objective is to compare infection-related hospital length of stay between participants treated with daptomycin and vancomycin. Secondary objectives were to compare participant reported outcomes (pain symptoms and Health Related Quality of Life), 30 day cSSSI-related hospital readmission rates, and cSSSI-related medical resource utilization and costs between participants treated with daptomycin and vancomycin. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00210899 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
| Recruiting |
NCT02566928 -
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence
|
Phase 4 | |
| Completed |
NCT00228982 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
| Completed |
NCT01105767 -
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
|
N/A | |
| Completed |
NCT01030731 -
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
|
Phase 1 | |
| Completed |
NCT00475930 -
Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates
|
N/A | |
| Completed |
NCT02814916 -
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
|
Phase 3 | |
| Completed |
NCT00513799 -
The Natural History of Community-Associated MRSA Infections and Decolonization Strategies
|
N/A | |
| Completed |
NCT00737269 -
A Complicated Skin and Soft-tissue Infection Patient Registry
|
Phase 4 | |
| Completed |
NCT00719810 -
Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections
|
Phase 2 | |
| Completed |
NCT01026740 -
Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT00492271 -
First Time in Man Trial for Friulimicin B
|
Phase 1 | |
| Completed |
NCT00731783 -
Staphylococcus Aureus Decolonization Study
|
N/A | |
| Completed |
NCT01018641 -
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
|
Phase 1 | |
| Terminated |
NCT00463801 -
Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections
|
Phase 4 | |
| Completed |
NCT02582203 -
Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA
|
Phase 4 | |
| Completed |
NCT00646958 -
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
|
Phase 2 | |
| Completed |
NCT00514527 -
A Study for Patients With Complicated Skin and Skin Structure Infections
|
Phase 2 | |
| Completed |
NCT01026558 -
A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients
|
Phase 1 | |
| Completed |
NCT01026636 -
A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age
|
Phase 1 |